12:00 AM
 | 
Jun 28, 2010
 |  BC Week In Review  |  Company News  |  Deals

Biovail, Valeant Pharmaceuticals International deal

Biovail will merge with fellow specialty pharma Valeant in a deal that would give Valeant shareholders about $3.2 billion in cash and Biovail stock. Valeant shareholders will receive a cash dividend of $16.77 and 1.7809 Biovail shares per Valeant share. Biovail shareholders will own about 50.5% of the combined company, with...

Read the full 235 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >